Bicycle Therapeutics PLC
NASDAQ:BCYC
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
13.52
27.51
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Bicycle Therapeutics PLC
Wall Street
Price Targets
BCYC Price Targets Summary
Bicycle Therapeutics PLC
According to Wall Street analysts, the average 1-year price target for
BCYC
is 38.76 USD
with a low forecast of 25.25 USD and a high forecast of 57.75 USD.
BCYC Last Price Targets
Bicycle Therapeutics PLC
The latest public price target was made on Oct 24, 2024 by
Jay Olson
from
Oppenheimer
,
who expects
BCYC
stock to
rise by 137%
over the next 12 months.
You can read more about this price target by viewing
the article on StreetInsider.
| Analyst | Price Target | Date | Article |
|---|---|---|---|
Jay Olson
Oppenheimer
|
48
USD
Upside 137% |
4 weeks ago
Oct 24, 2024
|
Oppenheimer Reiterates Outperform Rating on Bicycle Therapeutics (BCYC)
StreetInsider
|
|
Kalpit Patel
B.Riley Financial
|
28
USD
Upside 38% |
4 weeks ago
Oct 24, 2024
|
B.Riley Reiterates Neutral Rating on Bicycle Therapeutics (BCYC)
StreetInsider
|
|
Swayampakula Ramakanth
H.C. Wainwright
|
55
USD
Upside 171% |
2 months ago
Sep 16, 2024
|
H.C. Wainwright Reiterates Buy Rating on Bicycle Therapeutics (BCYC)
StreetInsider
|
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is BCYC's stock price target?
Price Target
38.76
USD
According to Wall Street analysts, the average 1-year price target for
BCYC
is 38.76 USD
with a low forecast of 25.25 USD and a high forecast of 57.75 USD.
What is Bicycle Therapeutics PLC's Revenue forecast?
Projected CAGR
30%
For the last 6 years the
compound annual growth rate for
Bicycle Therapeutics PLC's revenue is
54%.
The projected
CAGR
for the next 3 years is
30%.
You don't have any saved screeners yet
